Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) CFO Cecilia Jones Sells 1,780 Shares

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) CFO Cecilia Jones sold 1,780 shares of the stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $33.54, for a total transaction of $59,701.20. Following the sale, the chief financial officer now directly owns 30,049 shares of the company's stock, valued at $1,007,843.46. This represents a 5.59% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Agios Pharmaceuticals Price Performance

NASDAQ:AGIO traded up $0.94 on Thursday, hitting $33.65. 274,744 shares of the company's stock were exchanged, compared to its average volume of 653,135. The firm has a 50-day moving average price of $31.03 and a 200-day moving average price of $32.38. Agios Pharmaceuticals, Inc. has a 52 week low of $23.42 and a 52 week high of $62.58. The company has a market cap of $1.95 billion, a P/E ratio of 2.99 and a beta of 0.73.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.80) by $0.25. The business had revenue of $8.73 million for the quarter, compared to analyst estimates of $9.86 million. Agios Pharmaceuticals had a negative return on equity of 2.75% and a net margin of 1,798.26%. On average, research analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

Analyst Ratings Changes

AGIO has been the subject of a number of research analyst reports. Wall Street Zen lowered shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Monday, May 19th. Scotiabank cut their price target on Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating on the stock in a report on Friday, May 2nd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company. According to MarketBeat, Agios Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $58.60.

Hedge Funds Weigh In On Agios Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the company. Envestnet Asset Management Inc. lifted its stake in Agios Pharmaceuticals by 3.3% in the fourth quarter. Envestnet Asset Management Inc. now owns 24,805 shares of the biopharmaceutical company's stock valued at $815,000 after acquiring an additional 795 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Agios Pharmaceuticals by 9,296.6% in the 1st quarter. GAMMA Investing LLC now owns 8,175 shares of the biopharmaceutical company's stock valued at $240,000 after purchasing an additional 8,088 shares during the period. Venturi Wealth Management LLC acquired a new stake in Agios Pharmaceuticals in the 4th quarter valued at about $33,000. Vanguard Group Inc. grew its holdings in Agios Pharmaceuticals by 1.5% during the fourth quarter. Vanguard Group Inc. now owns 5,631,321 shares of the biopharmaceutical company's stock worth $185,045,000 after purchasing an additional 85,339 shares during the period. Finally, Northern Trust Corp raised its stake in Agios Pharmaceuticals by 0.9% in the fourth quarter. Northern Trust Corp now owns 595,480 shares of the biopharmaceutical company's stock valued at $19,567,000 after buying an additional 5,372 shares during the period.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.